LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, launches the Niagen+ NAD+ Test Kit*, now available exclusively through the company’s healthcare practitioner (HCP) channel. This innovative test kit provides practitioners with a reliable method for measuring patient blood NAD+ levels, helping them create more personalized and effective patient protocols using ChromaDex’s NAD+-boosting HCP products, Tru Niagen® and Niagen+..

洛杉矶——（商业新闻短讯）——全球烟酰胺腺嘌呤二核苷酸（NAD+）研究权威机构ChromaDex Corp.（纳斯达克代码：CDXC）推出了Niagen+NAD+测试试剂盒*，该试剂盒目前仅通过该公司的医疗保健从业者（HCP）渠道提供。这种创新的测试试剂盒为从业者提供了一种可靠的方法来测量患者血液NAD+水平，帮助他们使用ChromaDex的NAD+增强HCP产品Tru Niagen®和Niagen+创建更个性化和有效的患者协议。。

Tru Niagen is a suite of oral dietary supplements featuring Niagen (patented nicotinamide riboside or NR), the most efficient and high-quality NAD+ precursor available. Niagen+ features pharmaceutical-grade Niagen (patented nicotinamide riboside chloride or NRC) and will soon be available as Niagen IV and injections exclusively at clinics from U.S.

Tru Niagen是一套口服膳食补充剂，其特征是Niagen（获得专利的烟酰胺核苷或NR），这是最有效和高质量的NAD+前体。尼亚根+具有药物级尼亚根（专利烟酰胺核苷氯化物或NRC），很快将作为尼亚根IV和注射仅在美国诊所提供。

FDA 503B-registered outsourcing facilities with a prescription. Representing a significant advancement in intravenous NAD+ therapy, practitioners are eager to provide Niagen IV therapy to patients..

美国食品和药物管理局503B登记了外包设施并开具了处方。代表着静脉NAD+治疗的重大进步，从业者渴望为患者提供尼亚根IV治疗。。

Rob Fried, CEO of ChromaDex and Founder of Tru Niagen, noted, 'Our healthcare practitioners have requested a tool to measure blood NAD+ levels, and we believe this is the best product now available on the market.'

ChromaDex首席执行官兼Tru Niagen创始人罗伯·弗里德（RobFried）指出，“我们的医疗保健从业人员要求提供一种测量血液NAD+水平的工具，我们相信这是目前市场上最好的产品。”

Setting a new standard in analytical NAD+ measurement methods, the Niagen+ NAD+ Test Kit features cutting-edge dried blood spot (DBS) assay technology, ensuring the stability of NAD+ samples during transport for precise and accurate results. Other test kits use a less reliable DBS card, which requires adding a fixer solution to stabilize NAD+, which often degrades during the DBS drying process.

Niagen+NAD+测试试剂盒在分析NAD+测量方法方面树立了新标准，采用了先进的干血斑（DBS）分析技术，确保了NAD+样品在运输过程中的稳定性，从而获得精确准确的结果。其他测试试剂盒使用不太可靠的DBS卡，这需要添加固定剂溶液来稳定NAD+，NAD+在DBS干燥过程中经常降解。

With this innovative Niagen+ NAD+ test, HCPs can provide patients with personalized and effective protocols by more accurately tracking NAD+ changes over time..

通过这种创新的Niagen+NAD+测试，HCPs可以通过更准确地跟踪NAD+随时间的变化，为患者提供个性化和有效的方案。。

Key Niagen+ NAD+ Test Kit features:

Niagen+NAD+测试套件的主要功能：

Innovative test card technology: A unique blood spot test card maintains the stability of NAD+ throughout the transport process and ensures accurate measurement.

创新的测试卡技术：独特的血斑测试卡在整个运输过程中保持NAD+的稳定性，并确保准确的测量。

Baseline and progress tracking: While each HCP will determine the patient protocol, the test can be used to understand NAD+ levels before Tru Niagen NAD+-boosting and/or Niagen IV and injections to establish a baseline and again after NAD+ boosting therapy to track changes.

基线和进展跟踪：虽然每个HCP将确定患者方案，但该测试可用于了解Tru Niagen NAD+增强和/或Niagen IV和注射前的NAD+水平，以建立基线，并在NAD+增强治疗后再次跟踪变化。

Validated, trusted results: Analyses are conducted at a Clinical Laboratory Improvement Amendments (CLIA) and the College of American Pathologists (CAP) accredited clinical genomics and biochemical testing laboratory with expertise in mass spec-based assays.

经过验证，可信的结果：分析是在临床实验室改进修正案（CLIA）和美国病理学家学院（CAP）认可的临床基因组学和生化测试实验室进行的，该实验室在基于质谱的分析方面具有专业知识。

Precision analysis: NAD+ measurements are conducted on the blood sample affixed to the DBS card using the gold standard analytical method, high-resolution liquid chromatography/tandem mass spectrometry (LC-MS/MS).

精密度分析：使用金标准分析方法，高分辨率液相色谱/串联质谱（LC-MS/MS），对附着在DBS卡上的血液样本进行NAD+测量。

How it works:

工作原理：

HCPs will provide patients with an at-home Niagen+ NAD+ Test Kit, which patients will register on the 1health platform. Once registered, the patient will follow the instructions within the kit to procure a sample with the DBS card and send it to the lab using a prepaid envelope. Results will be available to both patients and doctors in about two weeks through 1health..

HCPs将为患者提供一个家庭Niagen+NAD+检测试剂盒，患者将在1health平台上注册。注册后，患者将按照试剂盒中的说明使用DBS卡获取样品，并使用预付信封将其发送到实验室。通过1health，患者和医生将在大约两周内获得结果。。

Mehdi Maghsoodnia, CEO at 1health, emphasized the critical role of 1health’s platform in the successful launch of the Niagen+ NAD+ Test Kit. “We are proud to partner with ChromaDex to bring this innovative testing solution to healthcare practitioners. Our robust software seamlessly integrates with both the warehouse and the lab, ensuring efficient fulfillment of kits and accurate delivery of results.

1health首席执行官Mehdi Maghsoodnia强调了1health平台在成功推出Niagen+NAD+测试套件中的关键作用。“我们很荣幸与ChromaDex合作，为医疗保健从业者带来这一创新的测试解决方案。我们强大的软件与仓库和实验室无缝集成，确保高效完成试剂盒和准确交付结果。

This collaboration provides invaluable insights for practitioners aiming to optimize their patients' NAD+ levels, enabling personalized and effective NAD+ boosting protocols, such as Tru Niagen oral supplementation and soon Niagen IV and injection, to maximize therapeutic outcomes.”.

这种合作为旨在优化患者NAD+水平的从业者提供了宝贵的见解，从而实现个性化和有效的NAD+促进方案，例如Tru-Niagen口服补充剂以及不久的Niagen IV和注射，以最大程度地提高治疗效果。”。

Practitioners can learn more about the test kit, view all HCP products, and find research on clinical practice applications at www.truniagenpro.com. To learn more about ChromaDex, please visit www.chromadex.com.

从业者可以在www.truniagenpro.com上了解有关测试试剂盒的更多信息，查看所有HCP产品，并找到有关临床实践应用的研究。要了解有关ChromaDex的更多信息，请访问www.ChromaDex.com。

*This product is not intended to diagnose, prevent, or treat a condition. Measurements and statistics are intended for informational and educational purposes only, to support general health and wellness. This product has not been tested with individuals with health conditions and has not been cleared or approved by the U.S.

*本产品不用于诊断、预防或治疗疾病。测量和统计仅用于信息和教育目的，以支持一般健康和福祉。该产品尚未与健康状况良好的个人进行测试，也未获得美国的许可或批准。

Food and Drug Administration..

美国食品药品监督管理局。。

Forward-Looking Statements:

前瞻性声明：

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to the Niagen+ NAD+ Test Kit, now available exclusively through the company’s healthcare practitioner (HCP) channel.

。

Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as 'expects,' 'anticipates,' 'intends,' 'estimates,' 'plans,' 'potential,' 'possible,' 'probable,' 'believes,' 'seeks,' 'may,' 'will,' 'should,' 'could' or the negative of such terms or other similar expressions.

不描述历史事实的陈述构成前瞻性陈述，通常（但不总是）可以通过使用诸如“期望”、“预期”、“打算”、“估计”、“计划”、“潜在”、“可能”、“可能”、“相信”、“寻求”、“可能”、“意志”、“应该”、“可能”或这些术语或其他类似表达的否定词来识别。

Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition.

导致这些前瞻性声明不确定性的风险包括新型冠状病毒对我们的业务和全球经济的影响；我们的经营亏损历史以及需要获得额外融资；我们产品销售的增长和盈利能力；我们保持销售、营销和分销能力的能力；改变消费者对我们产品的看法；我们依赖单一或有限数量的第三方供应商；以及与我们的业务和财务状况相关的风险和不确定性。

More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov.

有关ChromaDex和可能影响前瞻性陈述实现的风险因素的更多详细信息，请参阅ChromaDex截至2023年12月31日的10-K表年度报告、ChromaDex的10-Q表季度报告以及ChromaDex提交给SEC的其他文件，其副本可从SEC网站www.SEC.gov获得。

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date he.

提醒读者不要过度依赖这些前瞻性声明，这些声明仅在他发表之日起生效。

About ChromaDex:

关于ChromaDex：

ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+.

ChromaDex Corp.（纳斯达克：CDXC）是烟酰胺腺嘌呤二核苷酸（NAD+）的全球权威，专注于健康衰老科学。ChromaDex团队由世界著名科学家组成，与来自全球知名大学和研究机构的独立调查人员合作，以揭示NAD+的全部潜力。

A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality..

NAD+是人体每个细胞中发现的一种重要辅酶，随着年龄的增长和暴露于其他日常压力源而下降。NAD+耗竭是与年龄相关的健康和活力变化的原因。。

Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available.

ChromaDex将其作为科学严谨性、安全性、质量和透明度的黄金标准，是其经临床验证的旗舰成分Niagen（获得专利的烟酰胺核苷或NR）的创新者，Niagen是最有效和最优质的NAD+助推器。

Niagen® is the active ingredient in ChromaDex’s consumer products, sold as the brand Tru Niagen®, the number one healthy-aging NAD+ supplement in the United States†. Clinically proven to increase NAD+ levels, Tru Niagen is helping people around the world transform the way they age (available at www.truniagen.com)..

Niagen®是ChromaDex消费品中的活性成分，以Tru Niagen®品牌出售，Tru Niagen®是美国排名第一的健康衰老NAD+补充剂†。临床证明，Tru Niagen可以提高NAD+水平，正在帮助世界各地的人们改变他们的衰老方式（可从www.truniagen.com获得）。。

ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com, where copies of press releases, news, and financial information are regularly published.

ChromaDex强大的专利组合保护NR和其他NAD+前体。ChromaDex在www.ChromaDex.com上维护一个网站，定期发布新闻稿、新闻和财务信息的副本。

†Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024).

†根据美国最大电子商务市场（截至2023年3月1日至2024年2月29日）收入最高的膳食补充剂品牌。